Maribel is currently Senior Principal Scientist in the South San Francisco PDMB ADME organization. She received her degree in Biochemistry in 1995 from the National Institute of Applied Sciences in Lyon, France and her Ph.D in 1999 from the University of Nottingham in the UK.
After 4 years training in protein separation and mass spectrometry at Amersham Biosciences UK, Maribel joined the mass spectrometry group at Schering-Plough in Palo Alto. Over the years, Maribel and her LC-MS group have supported the discovery and validation of novel biomarkers by mining proximal fluids from animal models, the characterization and quantitation of biologics in protein preps and biomatrices for multiple discovery programs to enable PCC, the LC-MS bioanalysis of small molecules, peptides and complex biologics as well as biotransformation of biologics. She has also led the Protein Sciences and PPDM efforts for several discovery programs, represented ADME and regulated BA on a program in clinical development, co-led the Merck internal initiative on Biotransformation Guidelines, and represented Merck for the IQ ADC working group. In 2022, Maribel co-founded and continues to co-lead the capABILITY chapter at Merck SSF. In her current role, Maribel is an ADME lead for discovery complex therapeutics programs and a scientific lead for modernization and automation of PDMB workflows in SSF, Boston and Westpoint. Her research interest lies in the biotransformation of biologics and how structural analysis can help understand and predict biotransformation. She is an author in over 20 scientific peer-reviewed publications.